Wave Life Sciences: Reversing Stock Losses Tricky Despite Near-Term AATD Readout
The analysis maintains a 'Hold' view of Wave Life Sciences, citing limited near-term upside amid competition in obesity and AATD. It notes WVE-007’s roughly 1% weight loss at six months versus GLP-1 peers and points to upcoming WVE-006 AATD data as a key catalyst.
Why it matters — WVE watchers may weigh the reported obesity-program results against the pending WVE-006 readout and its planned registrational trial.